P53 regulates the mevalonate pathway in human glioblastoma multiforme

Cell Death and Disease

Volumn 6, Issue 10, 2015, Pages

  Laezza, C ^a   D'Alessandro, A ^b,c   Croce, L Di ^d   Picardi, P ^b,c   Ciaglia, E ^b,c   Pisanti, S ^b,c   Malfitano, A M ^b,c   Comegna, M ^e,f   Faraonio, R ^e,f   Gazzerro, P ^b,c   Bifulco, M ^b,c  

^a CNR   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYL DIPHOSPHATE; FARNESYL TRANSFERASE 1; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; MEVALONATE KINASE; MEVALONIC ACID; PROTEIN P53; TRANSFERASE; UNCLASSIFIED DRUG; CHOLESTEROL; TP53 PROTEIN, HUMAN;

ARTICLE; ASTROCYTE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; BIOSYNTHESIS; BRAIN TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CHOLESTEROL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84975230142     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.279     Document Type: Article

References (39)

1. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18: 54-61.
2. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004; 229: 567-585.
3. Quesney-Huneeus V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979; 76: 5056-5060.
4. Schmidt RA, Schneider CJ, Glomset JA. Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J Biol Chem 1984; 259: 10175-10180.
5. El-Sohemy A, Archer MC. Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations. Carcinogenesis 2000; 21: 827-831.
6. Bennis F, Favre G, Le Gaillard F, Soula G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 1993; 55: 640-645.
7. Harwood Jr HJ, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J Lipid Res 1991; 32: 1237-1252.
8. Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S et al. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: Possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 1990; 50: 3270-3273.
9. Duncan RE, El-Sohemy A, Archer MC. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclindependent kinase-2 activity. J Biol Chem 2004; 279: 33079-33084.
10. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010; 17: 348-361.
11. Tennant DA, Durán RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis 2009; 30: 1269-1280.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
13. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
14. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med 2011; 89: 237-245.
15. Larsson O. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol 1996; 22: 197-212.
16. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 1992; 339: 1154-1156.
17. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-614.
18. Millau JF, Bastien N, Drouin R. p53 transcriptional activities: a general overview and some thoughts. Mutat Res 2009; 681: 118-133.
19. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 2010; 17: 982-989.
20. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA 2002; 99: 8467-8472.
21. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23: 4878-4884.
22. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012; 148: 244-258.
23. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 1996; 66: 710-716.
24. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 2010; 107: 15051-15056.
25. Inoue N, Shimano H, Nakakuki M, Matsuzaka T, Nakagawa Y, Yamamoto T, Sato R et al. Lipid synthetic transcription factor SREBP-1a activates p21WAF1/CIP1, a universal cyclindependent kinase inhibitor. Mol Cell Biol 2005; 25: 8938-8947.
26. Pfrieger FW, Ungerer N. Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res 2011; 50: 357-371.
27. Jen KY, Cheung VG. Identification of novel p53 target genes in ionizing radiation response. Cancer Res 2005; 65: 7666-7673.
28. Botcheva K, McCorkle SR, McCombie WR, Dunn JJ, Anderson CW. Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle 2011; 10: 4237-4249.
29. Kim E, Giese A, Deppert W. Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem Pharmacol 2009; 77: 11-20.
30. Aylon Y. Oren M living with p53, dying of p53. Cell 2007; 130: 597-600.
31. Yongjun Y, Shuyun H, Lei C, Xiangrong C, Zhilin Y, Yiquan K. Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression. J Neuroimmunol 2013; 260: 1-8.
32. Haar CP, Hebbar P, Wallace 4th GC , Das A, Vandergrift 3rd WA , Smith JA et al. Drug resistance in glioblastoma: a mini review. Neurochem Res 2012; 37: 1192-1200.
33. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: P53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67: 11886-11895.
34. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006; 96: 766-776.
35. Riganti C, Castella B, Kopecka J, Campia I, Coscia M et al. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLOS One 2013; 8: e60975.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methods. Methods 2001; 25: 402-408.
37. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-915.
38. Gjoerup O, Zaveri D, Roberts TM. Induction of p53-independent apoptosis by simian virus 40 small t antigen. J Virol 2001; 75: 9142-9155.
39. Perillo B, Tedesco I, Laezza C, Santillo M, Romano A, Aloj SM et al. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in FRTL-5 cells. II. Downregulation by v-K-ras oncogene. J Biol Chem 1995; 270: 15237-15241.